Figure 3: Survivorship analysis among patients treated with Efavirenz (EFV)- based regimens and Nevirapine (NVP)-based regimens. Time to death (HR = 1.104, 95% confidence interval [CI]: 0.671 to 1.815; P = 0.698; not significant).